Separate Licence Needed to Sell Bulk Drugs in Wholesale: Centre Proposes

Separate Licence Needed to Sell Bulk Drugs in Wholesale: Centre Proposes

Wholesale pharmaceutical traders dealing in active and inactive bulk drug substances across India will soon need to obtain a dedicated wholesale licence distinct from finished formulations under a sweeping regulatory overhaul proposed by the Union Ministry of Health and Family Welfare. Outlined through draft amendments to the Drugs Rules, 1945 (notified under Draft Gazette Notification G.S.R. No. 987(E) and publicized on November 19, 2026), the proposal introduces a separate application form (Form 19-BC) and a dedicated wholesale licence (Form 20-BC) specifically for trading in bulk drugs, including active pharmaceutical ingredients (APIs) and excipients. Currently, a single common licence covers the wholesale distribution of both finished formulations and raw bulk substances, making it harder for regulators to track ingredient movement, enforce cold-chain or handling norms, and prevent adulteration—an issue that drew intense scrutiny following past incidents involving contaminated industrial solvents in cough syrups. Endorsed earlier by the Drugs Consultative Committee (DCC) at its 67th meeting on November 17, 2025, and the Drugs Technical Advisory Board (DTAB) at its 93rd meeting on February 16, 2026, the framework mandates that bulk drugs be sold under the personal supervision of a competent person and clearly record categories handled—including substances governed by the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985. Alongside the bulk-drug licensing reform, the Health Ministry has also proposed embedding Good Storage and Distribution Practices (GSDP) into the Drugs Rules, 1945, extending targeted manufacturing relaxations under revised Schedule M for medicinal gases, empty gelatin capsules, and disinfectant fluids, and bringing antimicrobial drugs under central "new drug" approval rules via amendments to the New Drugs and Clinical Trials Rules, 2019. For pharmaceutical manufacturers, wholesale stockists, hospital pharmacists, and consumers across Unnao, Lucknow, Kanpur, Varanasi, Hyderabad, Ahmedabad, Mumbai, and New Delhi, these four interconnected reforms aim to safeguard medicine quality from raw-material sourcing all the way to the patient.

Union Health Ministry Drug-Rule Reforms (Nov 2026): Complete Snapshot

To bring together the four regulatory proposals unveiled by the Union Ministry of Health and Family Welfare across the Drugs Rules, 1945 and the New Drugs and Clinical Trials Rules, 2019, the table below summarizes each change and its practical impact:

Regulatory Reform Area Proposed Rule & Form Changes Implementation Timeline & Supply-Chain Impact
1. Separate Bulk-Drug Wholesale Licence Amends Drugs Rules, 1945 to introduce Form 19-BC (application) and Form 20-BC (licence) for wholesale trade in active and inactive bulk drugs, separate from finished formulations; records categories including NDPS Act, 1985 substances and requires personal supervision by a competent person. Existing licensees receive a transition window until expiry of their current retention period or 12 months after final notification, whichever is later; public comments open for 30 days.
2. Good Storage & Distribution Practices (GSDP) Incorporates formal GSDP guidelines into the Drugs Rules, 1945 governing procurement, storage, transport, distribution, and record-keeping across the supply chain. Protects potency, safety, and integrity of medicines as products pass from manufacturers and importers through wholesalers and stockists to patients.
3. Targeted Schedule M Manufacturing Relaxations Amends Drugs Rules, 1945 to retain product-specific exemptions under revised Schedule M for medicinal gases, empty gelatin capsules, and disinfectant fluids. Allows licensing authorities to apply appropriate quality standards without imposing unsuited pharmaceutical plant requirements on specialized non-standard lines.
4. Central Oversight for Antimicrobial Drugs Draft amendments to the New Drugs and Clinical Trials Rules, 2019 (notified in early November 2026) classify antimicrobials within the "new drug" framework. Requires Central Licensing Authority (CDSCO) approval before manufacturers apply for state manufacturing licences, strengthening quality checks to combat antimicrobial resistance (AMR).

Why Bulk Drugs Are Being Separated From Finished Formulations

Until now, wholesale pharmaceutical dealers operating under a single common licence could trade both packaged formulations and bulk raw substances without distinct category-specific disclosures or dedicated supervision norms. By carving out Form 19-BC and Form 20-BC exclusively for bulk drugs, the Health Ministry aims to give central and state drug inspectors clear visibility into who trades active pharmaceutical ingredients, excipients, and controlled substances covered under the NDPS Act, 1985. Requiring every wholesale transaction of bulk substances to occur under the personal oversight of a qualified, competent person—while granting existing businesses either until the end of their current licence retention cycle or 12 months post-final notification to transition—balances stricter traceability with practical compliance time for legitimate traders.

GSDP Standards, Schedule M Tailoring, and Tighter Antimicrobial Checks

Beyond wholesale licensing, the Health Ministry's broader package addresses quality gaps at both ends of the pharmaceutical lifecycle. Embedding Good Storage and Distribution Practices (GSDP) into statutory rules establishes enforceable benchmarks for temperature control, warehousing, transit conditions, and documentation so medicines do not degrade between factory gate and pharmacy counter. At the manufacturing stage, preserving tailored Schedule M provisions for medicinal gases, empty gelatin capsules, and disinfectant liquids ensures proportional regulation suited to their distinct production processes. Meanwhile, bringing antimicrobials under the New Drugs and Clinical Trials Rules, 2019 mandates prior central scrutiny of safety, efficacy, and quality before state licences are granted—a direct regulatory strike against substandard antibiotics that accelerate antimicrobial resistance (AMR). Stakeholders and members of the public have 30 days from the availability of the Gazette notification to submit objections or suggestions to the Under Secretary (Drugs), Ministry of Health and Family Welfare.